Where: OnlineWhen: 9am – 1pm, Tuesday, 27th April 2021 ACI Regulatory and Compliance Associate Dr Parveen Bhatarah will be speaking at this upcoming conference, hosted by… Read More »27 April: New and emerging novel foods – the UK regulatory system, market development, safety, and innovation in the food sector
ACMD has been commissioned to provide impartial and independent scientific advice on the acceptable levels of constituent cannabinoids in CBD products marketed as consumer products. In this member event ACI will gather input from our members for our response.
ACI today publicly rebuts the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
On Friday 26 March 2021, ACI representatives met with the FSA for clarification relating to the novel foods validation process and the publication of the list that they mentioned in their update on 12 March.
Results from a major US trial over 800 people over the past seven months found CBD use has zero impact on the liver. ACI member, Columbia Care, Charlotte’s Web and 10 other US companies provided around $1m for a trial which started last summer – and now appears to have answered the CBD safety question.
This ACI members event will be hosted by Senior Trading Standards Officers. The webinar will provide an opportunity for ACI members to get to know and… Read More »Trading Standards Partnership Advisory Meeting
CBD industry experts have put together a detailed safety review of THC recommending clear policy recommendations to cut market confusion reports NutraIngredients
Canex cover news of the release of our detailed safety review report on THC.
Experts from the Association for the Cannabinoid Industry (ACI) and Centre for Medicinal Cannabis (CMC) have put together a detailed safety review paper of THC – Health Guidance Levels for THC in CBD products: Safety Assessment & Regulatory Recommendations. The paper recommends further research and makes policy recommendations.
